GLP1-RA - A pathway to Comprehensive Metabolic Care with Evidence - PES Midsummer Conference 2026

TLDR;

The video presents a talk from the 12th Midsummer Pakistan Endocrine Society conference about GLP receptor agonists in metabolic care, focusing on the efficacy of biosynthetic semaglutide in treating type 2 diabetes. This treatment aids in significant glycemic and weight management, addressing the high prevalence of diabetes in Pakistan.

• The study presents that one out of three adults in Pakistan is affected by diabetes.
• Results indicate substantial improvements in HbA1c levels and weight management in patients treated with semaglutide.

Introduction and Panel Discussion [0:00]

Dr. Arshad Dusen Sab, a consultant endocrinologist, introduces the session and panel participants at the conference. He emphasizes the importance of addressing obesity as it contributes significantly to metabolic diseases like hypertension and diabetes.

Background on Diabetes in Pakistan [2:20]

The discussion reveals that Pakistan has a staggering diabetes burden, with current statistics indicating that one in three adults has diabetes, signaling a rise from previous estimates. The implication is that more individuals are either undiagnosed or prediabetic.

Role of Semaglutide and GLP-1 Agonists [4:30]

Dr. Dusen elaborates on semaglutide as a dual-action GLP-1 receptor agonist, aiding both glucose and weight control, which in turn reduces cardiovascular events. He explains the drug's production via recombinant DNA technology and contrasts it with biosynthetic peptide production, highlighting the differences in approval processes and safety profiles.

Synthetic Peptides Production and Safety [7:40]

The synthesis of biosynthetic peptides requires less extensive clinical trials than recombinant biologics. The FDA defines peptides as amino acid chains of 40 or fewer. The benefits include consistent product safety, purity, and an absence of host cell impurities, making them a safer option for patients.

Real-World Evidence and Study Goals [10:00]

The study aims to bridge evidence gaps regarding biosynthetic semaglutide in real-world situations, focusing on glycemic control and quality of life. It had ethical approval and was registered as a multicenter study including various demographics from Pakistan.

Study Design and Patient Characteristics [13:10]

The study involved a prospective observational design enrolling 268 type 2 diabetes patients who were receiving semaglutide treatment. Key baseline characteristics included high BMI and varying comorbidities, with 81% starting with HbA1c levels above 8%.

Results – Glycemic Control [14:59]

The data shows a significant reduction in HbA1c levels, with 38% of participants achieving levels below 7% after six months, indicating effectiveness in lowering diabetes severity. Weight loss of over 5% was achieved in 76% of participants.

Impact on Comorbidities and Quality of Life [17:04]

A remarkable improvement was noted in additional health aspects, including a decrease in blood pressure and enhanced HDL levels, revealing comprehensive benefits beyond just glycemic control. Quality of life scores improved significantly by the study's end.

Medication Adherence and Patient Satisfaction [20:00]

Medication adherence rates were evaluated, with only about 37% of patients demonstrating high adherence to the regimen. Conclusively, patient satisfaction and perceptions of hypoglycemia risk improved, marking a relevant conclusion for treatment adherence.

Safety and Adverse Events [22:30]

Reported adverse events were minor, with gastrointestinal complaints being the most common. Only a few patients discontinued treatment due to side effects, suggesting that the overall treatment was well-tolerated.

Economic Impact and Conclusion [25:00]

The study points out economic advantages from reduced insulin dependencies and medication requirements, showing significant clinical effectiveness. The results assert the triple benefit of biosynthetic semaglutide, contributing to glycemic control, weight loss, and better patient quality of life.